Compare LCUT & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCUT | NERV |
|---|---|---|
| Founded | 1945 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 210.1M |
| IPO Year | 1996 | 2014 |
| Metric | LCUT | NERV |
|---|---|---|
| Price | $8.34 | $4.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 178.6K | 124.6K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $647,933,000.00 | $41,175,600.00 |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $1.57 |
| 52 Week High | $9.80 | $12.46 |
| Indicator | LCUT | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 36.85 |
| Support Level | $3.40 | $4.30 |
| Resistance Level | $9.80 | $4.50 |
| Average True Range (ATR) | 0.73 | 0.36 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 3.65 | 19.90 |
Lifetime Brands Inc is a U.S.-based company that designs, sources, and sells branded kitchenware, tableware, and other home solution products used in the home. The company's product portfolio comprises kitchen tools, cutlery, thermometers, cutting boards, spice racks, dinnerware, stemware, flatware, bath scales, thermal beverage ware, food storage, neoprene travel products, etc. These products are marketed under owned or licensed brands like Farberware, KitchenAid, Mikasa, Misto, Taylor, Sabatier, and Pfaltzgraff, among others. The company mainly sells its products directly to retailers and distributors, and a limited selection directly to consumers through its own websites. It has two reportable operating segments: U.S., which derives maximum revenue, and International.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.